

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 July 2023 (13.07.2023)



(10) International Publication Number
WO 2023/133375 A1

(51) International Patent Classification:

C07D 403/06 (2006.01) C07D 487/04 (2006.01)
C07D 403/14 (2006.01) C07D 401/14 (2006.01)
C07D 409/04 (2006.01) A61P 37/00 (2006.01)
C07D 471/04 (2006.01) A61P 9/10 (2006.01)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2023/060039

Published:

- with international search report (Art. 21(3))

(22) International Filing Date:

03 January 2023 (03.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/296,705 05 January 2022 (05.01.2022) US
63/435,654 28 December 2022 (28.12.2022) US

(71) Applicant: **BLOSSOMHILL THERAPEUTICS, INC.**
[US/US]; 3525 John Hopkins Court, Suite 100, San Diego,
California 92121 (US).

(72) Inventors: **CUI, Jingrong Jean**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US). **RUI, Eugene
Yuanjin**; 3525 John Hopkins Court, Suite 100, San Diego,
California 92121 (US). **ROGERS, Evan W.**; 3525 John
Hopkins Court, Suite 100, San Diego, California 92121
(US). **ZHAI, Dayong**; 3525 John Hopkins Court, Suite 100,
San Diego, California 92121 (US).

(74) Agent: **LIPTAK, Vincent P.**; BARNES & THORNBURG
LLP, Indianapolis, Indiana 46204 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS

(57) Abstract: The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as autoimmune disease.

WO 2023/133375 A1